Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E20.67 EPS (ttm)5.94 Insider Own0.02% Shs Outstand2.70B Perf Week3.94%
Market Cap331.70B Forward P/E16.63 EPS next Y7.38 Insider Trans-8.10% Shs Float2.70B Perf Month8.80%
Income16.54B PEG3.50 EPS next Q1.76 Inst Own67.00% Short Float0.58% Perf Quarter8.86%
Sales71.89B P/S4.61 EPS this Y8.30% Inst Trans-0.05% Short Ratio2.29 Perf Half Y4.10%
Book/sh26.73 P/B4.59 EPS next Y4.87% ROA- Target Price125.06 Perf Year17.78%
Cash/sh- P/C- EPS next 5Y5.91% ROE- 52W Range100.87 - 124.38 Perf YTD6.53%
Dividend3.20 P/FCF- EPS past 5Y11.20% ROI- 52W High-1.32% Beta0.78
Dividend %2.61% Quick Ratio- Sales past 5Y2.00% Gross Margin69.90% 52W Low21.68% ATR1.30
Employees127100 Current Ratio- Sales Q/Q1.70% Oper. Margin27.50% RSI (14)83.54 Volatility1.21% 1.02%
OptionableYes Debt/Eq- EPS Q/Q20.20% Profit Margin23.00% Rel Volume1.59 Prev Close121.70
ShortableYes LT Debt/Eq- EarningsJan 24 BMO Payout39.00% Avg Volume6.81M Price122.73
Recom2.50 SMA206.31% SMA506.45% SMA2005.44% Volume10,800,404 Change0.85%
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Feb-24-17 07:10PM  Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand at Motley Fool
04:53PM  Pfizers Valuation after Its 4Q16 Earnings Release
04:13PM  Dow closes at 11th straight record as stocks finish week higher at MarketWatch
02:17PM  3 All-or-Nothing Stocks We're Closely Watching at Motley Fool
07:39AM  Performance of Eli Lilly & Co.s Business Segments in 4Q16
06:20AM  Johnson & Johnson (JNJ) Up 6% Since Earnings Report: Can It Continue?
06:00AM  Morningstar's 5 Favorite Foreign-Stock ETFs at Morningstar
Feb-23-17 06:29PM  Dow Jones Leads Market Gains on Thursday
05:39PM  United Therapeutics feels squeeze from increased pulmonary hypertension competition at
04:36PM  Dow logs 10th straight record, but Nasdaq stumbles a second day at MarketWatch
04:01PM  Johnson & Johnson, Pfizer Lead DJIA Higher on Thursday
11:40AM  8 Dow Dividend Stocks You Can Buy and Hold Forever at Kiplinger
11:36AM  [$$] Fusion Pharmaceuticals Raises $25 Million for Targeted Cancer Therapies at The Wall Street Journal
Feb-22-17 07:01PM  Cramer: Buyers for Bristol-Myers Are Few and Far Between
03:02PM  Genmab and J&J's cancer drug set for blockbuster sales this year
02:26PM  Genmab's Darzalex could achieve peak annual sales of $9 bln -CEO
01:57PM  10 Companies With The Best Corporate Reputations
Feb-21-17 04:48PM  Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
04:41PM  3 Dividend Stocks for 2017
02:13PM  Bristol-Myers Buys Back Shares, Shuffles Board
11:25AM  Torax Medical agrees to sell to Johnson & Johnson subsidiary at
10:50AM  5 Safe Dividend Stocks to Buy for Retirement at Kiplinger
09:30AM  The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson
Feb-20-17 10:37AM  These Prescription Products Matter to Sanofis Growth
09:57AM  3 Stocks to Invest in Big Pharma at Motley Fool
Feb-19-17 06:16PM  Any Dip In Stocks Will Be A Gift To Buy at Forbes
01:20PM  The Natural Food Craze Is Now Sweeping Into Personal Care Products
Feb-18-17 03:23PM  Better Buy: Eli Lilly and Company vs. Johnson & Johnson at Motley Fool
Feb-17-17 03:27PM  Ethicon to acquire competitor at
12:20PM  11 Dow Stocks in Warren Buffett's Portfolio at Kiplinger
11:55AM  Billionaire Prem Watsas Fairfax Financial Holdings Boosts Stakes in Kennedy-Wilson, U.S. Bancorp, Johnson & Johnson at Insider Monkey
09:10AM  Geron (GERN) Q4 Earnings: What's in Store for the Stock?
08:13AM  Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
07:21AM  Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
Feb-16-17 01:51PM  [video]Hurry Up and Grab Some Johnson & Johnson Before the Stock Bursts Even More
11:41AM  How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners at Motley Fool
06:16AM  Sanofi Backtracked on Actelion Offer Price Amid J&J Talks at Bloomberg
04:50AM  How Sanofi lost out to J&J in $30 bln battle for Actelion Reuters
01:22AM  Actelion says J&J's $280 per share offer to start March 3
01:01AM  Johnson & Johnson publishes prospectus for Actelion tender offer GlobeNewswire
01:00AM  Johnson & Johnson Publishes Prospectus For Actelion Tender Offer PR Newswire
Feb-15-17 04:51PM  Top 4 Dividend Stocks for 2017 at Investopedia
11:49AM  Warren Buffett's billion dollar bet on Apple stock
11:30AM  Integra to buy J&J's Codman neurosurgery business for $1.05 bln
09:15AM  Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion
08:44AM  [$$] Integra Bids $1.05 Billion for J&J Neurosurgery Business at The Wall Street Journal
08:10AM  No Joke: Johnson & Johnson Could Grow Sales by 5% (or More) Annually Over the Next Decade at Motley Fool
07:21AM  Integra to buy J&J's Codman Neurosurgery business for $1.05 billion at MarketWatch
07:13AM  Integra offers to buy J&J's Codman neurosurgery business
07:00AM  Another Alzheimer's Drug Study Fails. This Time It's Merck's at Forbes
Feb-14-17 06:19PM  3 Stocks You Dont Have to Babysit at Motley Fool
05:06PM  Johnson & Johnson to Participate in Barclays Global Healthcare Conference PR Newswire
07:56AM  Early movers: HUM, AET, GM, PLKI, DISCA, GNRC, ITT & more at CNBC
01:48AM  Actelion, being bought by J&J, says FY core net income rose 27 pct
01:22AM  Actelion, being bought by J&J, says FY profit rose 26 pct
12:41AM  No Drugs for Back Pain, New Guidelines Say at The Wall Street Journal
Feb-13-17 06:45PM  [$$] GSK claims new HIV combination therapy will be 'less harmful' at Financial Times
06:24PM  4 Companies That Will Benefit From Trump's Repatriation Tax Reform
05:53PM  No Drugs for Back Pain, New Guidelines Say at The Wall Street Journal
05:33PM  4 Companies Affected by Strength of the US Dollar
04:12PM  Tampa business leaders speak out on incentives, tourism marketing during Gov. Scott's visit (Video) at
11:55AM  3 Dividend Stocks for 2017
Feb-12-17 07:43AM  3 Reasons Johnson & Johnson's Actelion Deal Might Not Be Totally Crazy at Motley Fool
Feb-10-17 04:01PM  Caterpillar, Nike Push Dow Higher Friday
03:42PM  3 Trump-Proof Dividend Stocks to Buy Right Now at Motley Fool
12:01PM  3 Stocks We'd Buy and Hold for the Next 20 Years at Motley Fool
10:49AM  Samuel Isaly Interview: How Healthcare Star Is Investing in Fast-Changing Sector
10:43AM  10 Most Diverse Companies In The US at Insider Monkey
09:33AM  This 50% Dividend Grower Is Hiding In Plain Sight at Forbes
08:41AM  EMA panel says that use of Actelion's Uptravi may continue Reuters
07:59AM  EMA panel recommends that use of Actelion's Uptravi may continue
Feb-09-17 12:58PM  Gilead to Battle GlaxoSmithKline for HIV Cure at Investopedia
09:52AM  3 Top Stocks for Low-Risk Investors at Motley Fool
Feb-08-17 06:05PM  Tweedy Browne Exits 2 Positions in 4th Quarter
12:42PM  Bayer's blood thinner also effective for artery disease Reuters
11:07AM  7 Dividend Growth Stocks On Sale at Insider Monkey
10:45AM  Just 2 of the 13 Largest Drugmakers Have More Cash Than Debt -- Can You Guess Who They Are? at Motley Fool
09:48AM  [$$] Sanofi points to lower profit for 2017 at Financial Times
Feb-07-17 03:54PM  These Are the 5 Perfect Dividend Stocks for Today's Market
12:53PM  Better Buy: Kimberly-Clark Corporation vs. Johnson & Johnson at Motley Fool
Feb-06-17 01:01PM  January a Banner Month for Global M&A Despite Uncertainty
09:55AM  Q4 Earnings Faring Well for Pharma ETFs
Feb-04-17 12:17PM  Johnson & Johnson Is Becoming a Far Riskier Investment at Motley Fool
06:41AM  Pfizer's New Biosimilar Is Off and Running at Motley Fool
Feb-03-17 05:05PM  Johnson & Johnson Unit Sued Over Leaking Breast Implants at Bloomberg
03:15PM  Erie County to sue pharmaceutical manufacturers over their part in opioid epidemic at
10:23AM  Merck's Sneak Peek Into Its Drug Pricing May Not Be Enough to Satisfy Skeptics at Motley Fool
Feb-02-17 12:00PM  Johnson & Johnson Adds Hospital Medical Devices to Sandra Peterson Responsibilities PR Newswire
09:52AM  Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
07:00AM  3 Pharmaceutical Stocks With Bigger Dividends Than Johnson & Johnson at Motley Fool
Feb-01-17 04:12PM  Roche CEO Shrugs Off Trump's Drug Stance; 2016 Sales Narrowly Miss
04:09PM  Lilly Hijacks J&J Diabetes Share In Q4; Trump-Rattled Sector Dips
03:17PM  Top Research Reports for February 1, 2017
01:19PM  Novartiss 4Q16 Earnings Meet Analysts Estimates
11:53AM  Pharmaceutical Executives From Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ) Met Trump at Insider Monkey
10:35AM  Bristol-Myers Squibbs Valuation Compared to Its Peers
08:14AM  Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys at Motley Fool
07:14AM  Drug Stocks Rally on Trump Meet with Pharma Bigwigs
12:51AM  [$$] Trumps Criticism of Imports Adds to Drugmakers Headaches at The Wall Street Journal
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM